RxDoctor Payments Data

Mark Bradford

Olympia, WANPI 1548335938

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 248 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,452 and has fallen 84.8% since, to $221 in 2022.

$3,630in general payments, 2019–2025

Across 248 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$702
  • AstraZeneca$568
  • Novo Nordisk$510
  • Dexcom, Inc.$363
  • Lilly USA, LLC$352
  • AbbVie$342
  • plus $792 from 15 others

What the payments were for

  • Food & beverage$3,60499%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →